David A. Siegel Vir Biotechnology, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 314,900 shares of VIR stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
314,900
Previous 112,700
179.41%
Holding current value
$1.83 Million
Previous $730,000
117.4%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VIR
# of Institutions
241Shares Held
109MCall Options Held
342KPut Options Held
150K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$96.8 Million0.67% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$95.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$76.7 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL12.9MShares$74.9 Million34.47% of portfolio
-
State Street Corp Boston, MA5.25MShares$30.5 Million0.0% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $769M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...